Clinical Trial Update: Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma [Phase 2]

View source ↗

Summary

Phase 2 trial of sunitinib malate in children with recurrent, refractory, or progressive malignant gliomas and ependymomas has completed; results were posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebellar Anaplastic Astrocytoma
• Cerebral Anaplastic Astrocytoma
• Cerebral Astrocytoma
• Infratentorial Ependymoma
• Mixed Glioma
• Oligodendroglioma
• Subependymal Giant Cell Astrocytoma
• Supratentorial Ependymoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma | Phase 2 | Status: COMPLETED | Results posted: 2015-03-23